AGP Picks
View all

Tech Times of New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.

Press releases published on October 24, 2026

JelluTide Gummies Introduces Jellu Tide Multi-Ingredient Dietary Supplement Formulation
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
DEEP Robotics Unveils Five Research Advances in Embodied AI
XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt
XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Lincoln Educational Services Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - LINC
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de de…
ROSEN, THE FIRST FILING FIRM, Encourages Netcapital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NCPL
ROSEN, THE FIRST FILING FIRM, Encourages Webull Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BULL
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
 Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Yangguang News Launches Global Youth Short Video Campaign “Me, Tang Poetry, and AI”
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Tech Times of New York

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.